Pulmosfere kao terapijski oblik dostave lijekova u pluća

master's thesis

• Title (english): Pulmosphere as a therapeutic system of drug delivery to the lungs
• Author: Matej Semren
• Mentor: Mario Jug (mentor)
• Committee member: Mario Jug (predsjednik povjerenstva)
• Committee member: Ivan Pepić (član povjerenstva)
• Committee member: Mario Gabričević (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmaceutical technology); Zagreb
• Defense date and country: 2016-09-14, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Da bi se uspješno dostavila određena, terapijski potrebna doza lijeka u pluća, treba treba uzeti u obzir fiziološke i
anatomske aspekte pluća osoba sa određenim plućnim bolestima, te promotriti promjene u apsorpciji, odlaganju i
klirensu lijeka. Pulmosfere su porozne čestice, formulirane od endogeno prisutnih ekscipijensa, veličine između 1-5
μm što im omogućuje odlaganje u donjim dišnim putevima. Izrađuju se tehnologijom sušenja raspršivanjem, te se
mogu oblikovati kao otopine, suspenzije ili... More nosači lijekova. Također se mogu formulirati kao FDC, odnosno dvije ili
više API se mogu koformulirati. Mogu se uklopiti u bilo koji sustav dostave (pMDI, PDI i li atomizatore). Prednosti su
im mogućnost uklapanja praktički bilo koje djelatne tvari, veliki raspon doza lijeka koji se može uklopiti te eliminacija
varijabilnosti između pacijenata, bilo varijabilnosti u odlaganju u gornjem respiratornom traktu, ili varijabilnosti
udaha, rukovanja uređajem ili varijabilnosti u FDCu. Do danas je registriran samo jedan lijek koji koristi ovu
tehnologiju, TOBI Podhaler, koji sadrži tobramicin, antiinfektiv registriran kod pacijenata sa cističnom fibrozom (za
eradikaciju P. Aeruginosa), ali postoji još određen broj lijekova u kliničkim ispitivanjima, za koje se očekuje da će
uskoro izaći na tržište. Less

Abstract (english)

To successfully deliver a certain, therapeuticaly needed drug dose into the lungs, phisiological and anatomicaI
aspects of the lungs of people with certain lung diseases need to be taken into account, as do changes in apsorption, deposition and clearance of the drug. Pulmosphere are porous particles, formulated from lung endogenous excipients,
with size rangeing from 1-5 μm, which allows them to be deposited into lower airways. They are produced
with the spray-drying technology, and can be... More formulated as solutions, suspensions or carriers of drugs. They can also be
formulated into a FDC, that is, two or more API can be coformulated, and can also be incorporeted into any
delivery system (pMDI, DPI, nebulizers). Their advantages include the possibility of formulating virtually any API
with the Pulmosphere technology, large dose range and elimination of interpatient variability, be it the upper
respiratory tract deposition variability, or variable inhalation profile/patient manuvers, and also eliminating FDC variability. To this date there is only one registered product using this technology, and it is the TOBl Podhaler, which includes tobramicyn, antiinfective registered for resolving chronic P. Aeruginosa infections in cystic fibrosis patients, but there are a number of other drugs facing clinical trials, expected to hit the market soon enough. Less

• Keywords: pluća; plućne bolesti; pulmosfere; primjena lijeka; pomoćne tvari; tehnologija pripreme; registrirani pripravci
• Keywords (english): lungs; lung diseases; pulmosphere; drug delivery; excipients; formulation technology; registered formulations
• Language: croatian
• URN:NBN: urn:nbn:hr:163:872190
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Reformatted digital
• Access conditions: Open access
• Created on: 2016-12-06 13:49:23